Everolimus for the treatment of advanced renal cell carcinoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1143-1155

  Amato, Robert ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Everolimus; mTOR inhibition; renal cell carcinoma; treatment

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; FAILURE TO THRIVE; FATIGUE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PANCREATITIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79953889736     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571382     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010 Sep-Oct;60(5):277-300
2. Beck SD, Patel MI, Synder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11:71-7
3. Motzer RJ, Backik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96 (Pubitemid 34032623)
4. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41 (Pubitemid 46224183)
5. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63 (Pubitemid 41079774)
6. Yang JC, Childs R Immunotherapy for renal cancer. J Clin Oncol 2006;24:5576-83
7. Garcia JA, Rini BL. Recent progress in the management of advanced RCC. CA Cancer J Clin 2007;57:112-25 (Pubitemid 46535711)
8. Crespo J, Hall M. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2002;66:579-91 (Pubitemid 35425110)
9. Dancey J. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28 (Pubitemid 40520970)
10. Bjornsti M, Houghton P. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48 (Pubitemid 38579480)
11. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition ofp21 translation. Cell 2005;120:747-59 (Pubitemid 40568794)
12. Powis G, Kirkpatrick L. Hypoxia inducible factor-1 (alpha) as a cancer drug target. Mol Cancer Ther 2004;3:647-54 (Pubitemid 39193744)
13. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17 (Pubitemid 39658341)
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colon cancer. N Engl J Med 2004;351:337-45 (Pubitemid 38944402)
15. Kris M, Natale R, Herbet R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, inh symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58 (Pubitemid 37432975)
16. Shepherd F, Rodrigues P, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32 (Pubitemid 41058344)
17. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
18. Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9 (Pubitemid 19213607)
19. Kodiaki T, Woscholski R, Hallberg B, et al. The activiation of phosphotidylinositol 3-kinase by RAS. Curr Biol 1994;4:798-806
20. Nicholson K, Anderson N. The protein kinase B/AKT signaling pathway in human malignancy. Cell Signal 2002;14:381-95 (Pubitemid 34214843)
21. deGraffenreid L, Friedrichs W, Russell D, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant AKT activity. Clin Cancer Res 2004; 10: 8059-67.
22. Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63 (Pubitemid 41079915)
23. Escudier B, Thompson J. Mechanism of action of everolimus in RCC. Med Oncol 2009;26(Suppl 3):S32-9
24. Pantuck A, Seligson D, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007;109:2257-67
25. Kenerson H, Aicher L, True L, et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5646-50
26. Dosquet C, Coudert M, Lepage E, et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8 (Pubitemid 28133167)
27. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7
28. Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23(6):4953-8 (Pubitemid 38182110)
29. Brugarolas J. Renal cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-7 (Pubitemid 46089681)
30. Patel P, Chadalavada R, Chaganti R, et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20 (Pubitemid 46095391)
31. Kondo K, Kim W, Lechpammer M, et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:439-44. Available from: http://biology. plosjournals.org/archive/1545-1885/1/3/pdf/10. 1371-journal.pbio.0000083-Lpdf
32. Thomas G, Tran C, Mellinghoff I, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7 (Pubitemid 43050086)
33. O'Donnell A, Faivre S, Burris H, et al. Phase I pharmacokinetic and pharmacodynamics study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
34. Amato R, Jac J, Giessinger S, et al. phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. ACS 2009;115(1):2438-46
35. Motzer R, Bacik J, Schwartz L, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63 (Pubitemid 41079774)
36. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-56
37. Motzer R, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. 2010 American Cancer Society. Cancer 2010;116(18):4256-65
38. Whorf R, Hainsworth J, Spigel D, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26(Suppl):abstract 5010
39. Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28(13):2131-6
40. Rosenberg J, Weinberg V, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell RCC. J Clin Oncol 2008;26(Suppl):abstract 5009
41. Giessinger S, Amato R, Jac J, et al. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer. J Clin Oncol 2008;26(Suppl):abstract 14603